Scientists test THC and Beta-Myrcene vapor in small human study
NCT ID NCT05432284
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-stage study will give 32 healthy adults who use cannabis vaporized THC, beta-myrcene, or a placebo to see how these substances affect their feelings of being high and sleepy. Researchers want to learn how beta-myrcene, a compound found in cannabis and other plants, changes the body's response to THC. The study is not yet recruiting and is run by Johns Hopkins University.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- THC (cannabis) and beta-myrcene vapor
- What this could lead to
- If successful, this could help understand how beta-myrcene changes the effects of THC, potentially leading to better-informed cannabis use.
- What could go wrong
- This is a very early Phase 1 study with only 32 participants, so results may not apply broadly. It measures subjective effects, not real-world outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 32 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2027
An estimate. Start dates often move.
- Expected to finish
-
Nov 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Have provided written informed consent 2. Be between the ages of 18 and 55 3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests 4. Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission 5. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission. 6. Have a body mass index (BMI) in the range of 18 to 36 kg/m2 7. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg 8. Have no allergies to any of the ingredients used to prepare vapor (delta 9-THC, myrcene). 9. Demonstrate competency on cognitive performance measures at screening visit (e.g., PASAT score over 75). Exclusion Criteria: 1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit; 2. History of or current evidence of significant medical (e.g. seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures. 3. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. 4. Use of a prescription medication (with the exception of birth control prescriptions) within 5 half-lives for that specific drug; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. 5. Cannabis use that is inconsistent with protocol requirements. 6. Clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina). 7. Individuals with anemia or who have donated blood in the prior 30 days
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis use are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Johns Hopkins School of Medicine Behavioral Pharmacology Research Unit
Baltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can rewards and remote coaching help people cut back on cannabis?
- Can a short tobacco break curb cannabis cravings?
- Texting teens to tame risky drinking and weed use?
- Can a blood pressure medication curb cannabis cravings?
- Could cannabis help fight diabetes? a study investigates
- A 5-session toolkit aims to curb teen cannabis use — will it work?